Fri Sep 20 13:00:00 UTC 2024: ## Oncolytics Biotech® Inc. Shows Promising Results in Breast Cancer Study, Driving Growth in Metastatic Breast Cancer Treatment Market

**PALM BEACH, Fla., Sept. 20, 2024 (GLOBE NEWSWIRE)** – The global metastatic breast cancer treatment market is experiencing significant growth, expected to reach $41.74 billion by 2030, according to a report by Strategic Market Research. This growth is driven by factors like increased investments in research and development, rising awareness of cancer diagnostics, and improved reimbursement policies.

Leading the charge in this growing market is Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage company specializing in immunotherapy for oncology. Oncolytics announced positive results from its BRACELET-1 study, a randomized Phase 2 trial evaluating pelareorep in patients with HR+/HER2- advanced or metastatic breast cancer.

**BRACELET-1 Study Highlights:**

* The study showed a significant improvement in overall survival (OS) for patients receiving pelareorep in combination with paclitaxel compared to paclitaxel monotherapy. Median OS was not reached in the pelareorep + paclitaxel arm, meaning more than half of the patients were still alive at the end of the study.
* The two-year survival rate for patients receiving pelareorep + paclitaxel was 64% compared to 33% for patients receiving paclitaxel monotherapy.
* The final median progression-free survival (PFS) was 12.1 months in the pelareorep + paclitaxel arm, compared to 6.4 months in the paclitaxel monotherapy arm.
* The overall response rate (ORR) was significantly higher for pelareorep + paclitaxel (37.5%) than for paclitaxel monotherapy (13.3%).

**Other Notable Cancer Developments:**

* Novartis AG (NYSE: NVS) received FDA approval for Kisqali® (ribociclib) in combination with an aromatase inhibitor (AI) for adjuvant treatment of HR+/HER2- early breast cancer (EBC) at high risk of recurrence.
* Merck (NYSE: MRK) received FDA approval for KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, for the first-line treatment of adult patients with unresectable advanced or metastatic malignant pleural mesothelioma (MPM).
* Pfizer Inc. (NYSE: PFE) announced its Phase 2 study of ponsegromab met its primary endpoint of change from baseline in body weight compared to placebo in people with cancer cachexia.
* Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) announced plans to broaden its drug development activities based on successful Phase 3 NASH study results and extended cash runway.

These developments highlight the ongoing progress in cancer treatment research and development, promising hope for patients battling these challenging diseases. Oncolytics’ promising BRACELET-1 results, combined with the broader market growth in metastatic breast cancer treatment, suggest a bright future for the company and the field as a whole.

Read More